Severe Gastrointestinal Disease People with inflammatory bowel disease, Crohns disease, or other serious GI conditions were largely excluded from retatrutide trials
Comparatively, 32,336 GLP-1 receptor agonists and 96,212 SGLT-2 inhibitor users were followed for a median of 1.2 and 1.2 years, respectively
Theres ongoing research on long-term safety and continued efficacy and benefits seen among different populations
A generic version of liraglutide received FDA approval recently and is available for as low as $221 per month with discount coupons, making it the cheapest FDA-approved brand-name GLP-1 injection on the market
There is no retail presence and you cannot receive medication without a clinician evaluation
Weight loss products frequently trend on social media, especially when they promise results that seem simple or effortless